Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8613732

— · A

8e0165d3-c18f-5ff1-b59d-e9c37ea71adf

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • UV_RESPONSE_DN+0.470
  • HEDGEHOG_SIGNALING+0.380
  • TGF_BETA_SIGNALING+0.380
  • MYOGENESIS+0.370
  • APICAL_JUNCTION+0.360
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
  • NOTCH_SIGNALING+0.330
  • ANGIOGENESIS+0.320
  • WNT_BETA_CATENIN_SIGNALING+0.260
  • PANCREAS_BETA_CELLS+0.240

Top 10 suppressed

  • MYC_TARGETS_V2-0.690
  • E2F_TARGETS-0.640
  • MYC_TARGETS_V1-0.600
  • G2M_CHECKPOINT-0.570
  • MTORC1_SIGNALING-0.530
  • OXIDATIVE_PHOSPHORYLATION-0.490
  • INTERFERON_ALPHA_RESPONSE-0.430
  • UNFOLDED_PROTEIN_RESPONSE-0.430
  • DNA_REPAIR-0.420
  • GLYCOLYSIS-0.410

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-HN-A2OB-01A-21R-A27Q-07
breast-umap@18
—A0.941
2TCGA-BH-A0EA-01A-11R-A115-07
breast-umap@18
—A0.933
3SRR8613726
breast-umap@18
—A0.930
4TCGA-EW-A1IX-01A-12R-A144-07
breast-umap@18
—A0.927
520050037.TNBC
breast-umap@18
—C0.906
6SRR35579834
breast-umap@18
—A0.904
7TCGA-SY-A9G0-01A-12R-A38B-07
bladder-landscape@3
——0.900
8TCGA-E9-A1NH-01A-11R-A14D-07
breast-umap@18
—A0.899
9TCGA-DK-A3IQ-01A-31R-A32Y-07
bladder-landscape@3
——0.899
10BSR_15_0097_A4_S88
breast-umap@18
—A0.897

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
UV_RESPONSE_DN0.470Inavolisib— uncovered
HEDGEHOG_SIGNALING0.380Inavolisib— uncovered
TGF_BETA_SIGNALING0.380Inavolisib— uncovered
MYOGENESIS0.370Inavolisib— uncovered
APICAL_JUNCTION0.360Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.350Inavolisib— uncovered
NOTCH_SIGNALING0.330Inavolisib— uncovered
ANGIOGENESIS0.320Remibrutinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.260Inavolisib— uncovered
PANCREAS_BETA_CELLS0.240Cobimetinib— uncovered
KRAS_SIGNALING_UP0.220Inavolisib— uncovered
COAGULATION0.210Binimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.170Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.160Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.160Inavolisib— uncovered
APICAL_SURFACE0.130Temsirolimus— uncovered
XENOBIOTIC_METABOLISM0.110Inavolisib— uncovered
APOPTOSIS0.100Idelalisib— uncovered
COMPLEMENT0.100Inavolisib— uncovered
P53_PATHWAY0.080Idelalisib— uncovered